Pharmacokinetics of doxorubicin in pregnant women

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 4, 2014, Pages 789-797

  Ryu, Rachel J ^a   Eyal, Sara ^a,f   Kaplan, Henry G ^b   Akbarzadeh, Arezoo ^a   Hays, Karen ^a   Puhl, Kristin ^a   Easterling, Thomas R ^a   Berg, Stacey L ^c   Scorsone, Kathleen A ^c   Feldman, Eric M ^d   Umans, Jason G ^e   Miodovnik, Menachem ^d   Hebert, Mary F ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SWEDISH MEDICAL CENTER   (United States)

^c TEXAS CHILDREN S CANCER CENTER   (United States)

^d Texas Children's Cancer Center ^*  (United States)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^f HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Adriamycin; Doxorubicin; Doxorubicinol; Pharmacokinetics; Pregnancy

Indexed keywords

DOXORUBICIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; PLASMA CONCENTRATION-TIME CURVE; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; THIRD TRIMESTER PREGNANCY;

ADMINISTRATION, INTRAVENOUS; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; YOUNG ADULT;

EID: 84898058860     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2406-z     Document Type: Article

References (42)

1. Cardonick E, Iacobucci A (2004) Use of chemotherapy during human pregnancy. Lancet Oncol 5:283-291
2. Lycette JL, Dul CL, Munar M et al (2006) Effect of pregnancy on the pharmacokinetics of paclitaxel: a case report. Clin Breast Cancer 7:322-324
3. Van Calsteren K, Verbesselt R, Ottevanger N et al (2010) Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study. Acta Obstet Gynecol Scand 89:1338-1345
4. Doll DC, Ringenberg QS, Yarbro JW (1988) Management of cancer during pregnancy. Arch Intern Med 148:2058-2064
5. Donegan WL (1983) Cancer and pregnancy. CA Cancer J Clin 33:194-214
6. Speth PA, van Hoesel QG, Haanen C (1988) Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 15:15-31
7. Chassany O, Urien S, Claudepierre P, Bastian G, Tillement JP (1996) Comparative serum protein binding of anthracycline derivatives. Cancer Chemother Pharmacol 38:571-573
8. Eksborg S, Ehrsson H, Ekqvist B (1982) Protein binding of anthraquinone glycosides, with special reference to adriamycin. Cancer Chemother Pharmacol 10:7-10
9. Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers CE (1983) Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res 43:3417-3421
10. Robert J, Bui NB, Vrignaud P (1987) Pharmacokinetics of doxorubicin in sarcoma patients. Eur J Clin Pharmacol 31:695-699
11. Piscitelli SC, Rodvold KA, Rushing DA, Tewksbury DA (1993) Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 53:555-561
12. Rodvold KA, Rushing DA, Tewksbury DA (1988) Doxorubicin clearance in the obese. J Clin Oncol 6:1321-1327
13. Hochster H, Liebes L, Wadler S et al (1992) Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 84:1725
14. Kassner N, Huse K, Martin HJ et al (2008) Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos 36:2113-2120
15. Robert J (1998) Anthracyclines. In: Grochow LB, Ames MM (eds) A clinician's guide to chemotherapy pharmacokinetics and pharmacodynamics. Williams & Wilkins, Baltimore, pp 93-173
16. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229
17. Takanashi S, Bachur NR (1976) Adriamycin metabolism in man. Evidence from urinary metabolites. Drug Metab Dispos 4:79-87
18. d'Incalci M, Broggini M, Buscaglia M, Pardi G (1983) Transplacental passage of doxorubicin. Lancet 1:75
19. Karp GI, von Oeyen P, Valone F et al (1983) Doxorubicin in pregnancy: possible transplacental passage. Cancer Treat Rep 67:773-777
20. Lambert J, Wijermans PW, Dekker GA, Ossenkoppele GJ (1991) Chemotherapy in non-Hodgkin's lymphoma during pregnancy. Neth J Med 38:80-85
21. García L, Valcárcel M, Santiago-Borrero PJ (1999) Chemotherapy during pregnancy and its effects on the fetus-neonatal myelosuppression: two case reports. J Perinatol 19:230-233
22. Thompson PA, Rosner GL, Matthay KK et al (2009) Impact of body composition on pharmacokinetics of doxorubicin in children: a glaser pediatric research network study. Cancer Chemother Pharmacol 64:243-251
23. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ (1992) Bioavailability of cyclosporine with concomitant rifampin administraiton is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 52:453-457
24. Hebert MF, Carr DB, Anderson GD, Blough D, Green GE, Brateng DA, Kantor E, Benedetti TJ, Easterling TR (2005) Pharmacokinetics and pharmacodynamics of atenolol during pregnancy and postpartum. J Clin Pharmacol 45:25-33
25. Benjamin RS, Riggs CE, Bachur NR (1973) Pharmacokinetics and metabolism of adriamycin in man. Clin Pharmacol Ther 14:592-600
26. Riggs CE, Benjamin RS, Serpick AA, Bachur NR (1977) Bilary disposition of adriamycin. Clin Pharmacol Ther 22:234-241
27. WHO (2013) Weight for age chart - Birth to 6 months girl's percentiles. http://www.who.int/childgrowth/standards/cht-wfa-girls-p-0-6.pdf. Accessed 05 May 2013
28. Dobbs NA, Twelves CJ, Gillies H, James CA, Harper PG, Rubens RD (1995) Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol 36:473-476
29. Rudek MA, Sparreboom A, Garrett-Mayer ES, Armstrong DK, Wolff AC, Verweij J, Baker SD (2004) Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer 40(8):1170-1178
30. Dodion P, Riggs CE, Akman SR et al (1984) Interactions between cyclophosphamide and adriamycin metabolism in rats. J Pharmacol Exp Ther 229:51
31. Nakai A, Sekiya I, Oya A, Koshino T, Araki T (2002) Assessment of the hepatic arterial and portal venous blood flows during pregnancy with Doppler ultrasonography. Arch Gynecol Obstet 266:25-29
32. Oppermann U (2007) Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing enzymes and their role in physiology. Annu Rev Pharmacol Toxicol 47:293-322
33. Iwata N, Inazu N, Satoh T (1990) Changes and localization of ovarian carbonyl reductase during pseudopregnancy and pregnancy in rats. Biol Reprod 43:397-403
34. Waclawik A, Jabbour HN, Blitek A, Ziecik AJ (2009) Estradiol-17beta, prostaglandin E2 (PGE2), and the PGE2 receptor are involved in PGE2 positive feedback loop in the porcine endometrium. Endocrinology 150:3823-3832
35. Jacquet JM, Bressolle F, Galtier M et al (1990) Doxorubicin and doxorubicinol: intra and inter-individual variations of pharmacokinetic parameters. Cancer Chemother Pharmacol 39:507
36. Hebert MF, Easterling TR, Kirby B et al (2008) Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin Pharmacol Ther 84:248-253
37. Davison JM, Dunlop W (1980) Renal hemodynamics and tubular function normal human pregnancy. Kidney Int 18:152-161
38. Elis A, Lishner M, Walker S, Atias D, Korenberg A, Koren G (2010) Doxorubicin in lymphoma: association between pharmacokinetic variability and clinical response. Ther Drug Monit 32:50-52
39. Cardonick E, Dougherty R, Grana G, Gilmandyar D, Ghaffar S, Usmani A (2010) Breast cancer during pregnancy: maternal and fetal outcomes. Cancer J 16:76-82
40. Legha SJ, Benjamin RS, McKay B (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous infusion. Ann Intern Med 96:133
41. Olson L, Bedja D, Alvey S, Cardounel A, Gabrielson K, Reeves R (2003) Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res 63:6602-6606
42. Lukaski H, Skiers W, Nielsen E, Hall C (1994) Total body water in pregnancy: assessment by using bioelectrical impedance. Am J Clin Nutr 59:578-585